GLP-1 receptor agonist for metabolic health support.
Compound_Description
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist with structural similarity to human GLP-1. This peptide has been extensively studied for its effects on glucose metabolism, appetite regulation, and body weight management.
The peptide works by binding to GLP-1 receptors in the pancreas, brain, and gastrointestinal tract. In the pancreas, it stimulates glucose-dependent insulin secretion and suppresses glucagon release. In the brain, it acts on appetite centers to reduce food intake. In the GI tract, it slows gastric emptying, contributing to increased satiety.
Semaglutide has a modified structure that provides resistance to DPP-4 enzyme degradation, resulting in a significantly longer half-life than native GLP-1. This allows for less frequent dosing and more sustained therapeutic effects.
Clinical trials have demonstrated significant effects on body weight, with participants experiencing substantial reductions over extended treatment periods. The peptide has also shown benefits for cardiovascular health markers and metabolic parameters.
Research_Applications
- GLP-1 receptor research
- Glucose metabolism studies
- Appetite regulation research
- Body weight studies
- Cardiovascular health research
Scientific_Studies
Semaglutide Weight Management Trial
Wilding JPH et al. published landmark trial results on Semaglutide and weight management.
Semaglutide Cardiovascular Outcomes
Marso SP et al. research on cardiovascular outcomes with Semaglutide.
STEP Trial Program
Comprehensive STEP trial program results for Semaglutide in obesity.
Semaglutide - SEM-2026-001
Research Use Only
This product is for laboratory research purposes only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease. Handle with appropriate laboratory safety equipment and procedures.